Hyderabad, Feb 19 (TNT): Dr. Reddy’s Laboratories on Thursday that it has acquired the trademarks of specialty brands Progynova® and Cyclo-Progynova® along with related assets for India from Mercury Pharma Group Limited, marking its entry into the hormone replacement therapy (HRT) segment.
In a release, the Hyderabad based pharma Giant said the acquisition strengthens its gynaecology portfolio and represents a strategic expansion into the HRT category in India.
Progynova® (estradiol valerate) is an oral hormone replacement therapy indicated for treating estrogen deficiency symptoms and preventing postmenopausal osteoporosis.
Cyclo-Progynova® (estradiol valerate and norgestrel) is a combined hormone replacement therapy providing both estrogen and progestogen components for treating estrogen deficiency symptoms.
According to IQVIA MAT December 2025 data cited by the company, Progynova® recorded sales of ₹100 crore and is the leading brand in the estradiol-represented pharmaceutical market in India.
M.V. Ramana, Chief Executive Officer – Branded Markets (India and Emerging Markets) at Dr. Reddy’s, said the acquisition would spearhead the company’s expansion into the HRT segment and enhance its existing gynaecology portfolio.
“With our established market access, we are uniquely positioned to extend the reach of the acquired assets and deliver greater impact,” Ramana said in a statement, adding that the move brings a first-in-class treatment closer to patients.
Founded in 1984 and headquartered in Hyderabad, Dr. Reddy’s operates across major global markets including the United States, India, Russia and CIS countries, China, Brazil and Europe.
TNT KS
Leave a Reply